Under the guidance of Dr Tom Lund, we are seeking to recruit a Higher Scientific Officer to be in charge of the development of high-throughput spatial biology technologies recently acquired by the IPU, namely the Leica CellDIVE and CosMx. The successful candidate will play a key role in the running of experiments/projects on these machines, establishment and maintenance of relevant SOPs, coordination of provision of relevant reagents through centralised ordering systems, as well as analysis, quality control and quality assurance of scientific data produced via the CellDIVE and CosMx. In addition, the HSO is expected to support all aspects of histopathology related to a range of research projects in our established, advanced translational research laboratory in the field of complex (IHC/RNA-ISH/mIF) tissue hybridisation technologies using Leica Bond and Ventana Discovery automated stainers.
About you
The successful candidate must have:
- MSc in Biological Sciences, Cancer Biology, Molecular Biology, Molecular Pathology, or a similar discipline (essential)
- PhD in Biological Sciences/Cancer Biology, Molecular Biology, Molecular Pathology, or a similar discipline (desirable)
- Knowledge of cancer, spatial and molecular biology
- Knowledge of histopathology, immunohistochemistry and multiplex immunofluorescence staining techniques
Department/Directorate Information
The Integrated Pathology Unit (IPU) is a joint venture between The Institute of Cancer Research (ICR) and the Royal Marsden Hospital (RMH), running an advanced translational tissue hybridization and digital pathology operation, with strong collaborative research and engagement with industry at its core.
Headed by Prof Manuel Salto-Tellez, and led by Dr Tom Lund, the IPU is a tissue-based laboratory with the mission to develop complex and highly quantitative approaches to tissue analysis (wet lab and in-silico) in the space of translational and clinical research, thus applicable in the context of clinical trials and adoption into diagnostic applications.
The IPU uses state-of-the-art tissue-based profiling such as single-plex immunohistochemistry (IHC), RNA in situ hybridization (ISH) and IHC/immunofluorescence multiplexing (mIF), together with multi-scan imaging and digital pathology/artificial intelligence biomarker quantitation.
Please visit our website https://www.cancerbrc.org/integrated-pathology-unit
What we offer
- A dynamic and supportive research environment
- Access to state-of-the-art facilities and professional development opportunities
- Collaboration with leading researchers in the field
- Competitive salary and pension
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Dr Thomas Lund via email on [email protected]